Skip to main content
. 2022 Jun 3;9(3):321–331. doi: 10.1007/s40801-022-00301-x

Table 2.

Ranking of the most reported adverse drug reactions 

ADR (PTName) Number of reports ROR Lower limit ROR Upper limit ROR Described in SmPC
Headache 143 2.11 1.77 2.51 Yes
Epistaxis 124 23.76 19.59 28.82 Yes
Anosmia 57 49.14 36.75 65.71 Yes
Dyspnoea 53 1.55 1.18 2.05 Yes
Palpitations 52 1.97 1.49 2.60 No
Therapeutic response unexpected 38 1.53 1.11 2.12 Not applicable
Dysgeusia 30 3.65 2.53 5.26 Yes
Ageusia 28 6.30 4.31 9.20 Yes
Parosmia 27 21.55 14.47 32.09 Yes
Nasal discomfort 24 56.02 35.76 87.77 Yes
Vision blurred 23 2.74 1.81 4.14 Yes
Anxiety 21 2.34 1.51 3.60 No
Nasal congestion 20 12.11 7.70 19.04 Yes
Visual impairment 20 2.13 1.37 3.32 Yes
Tinnitus 19 2.41 1.53 3.81 No
Throat irritation 16 7.61 4.61 12.56 Yes
Nasal septum perforation 14 463.23 186.65 1149.67 Yes
Migraine 14 2.37 1.40 4.03 No
Rhinorrhea 13 6.23 3.58 10.84 Yes
Dysphonia 13 3.30 1.90 5.72 Yes

ADR adverse drug reaction, PTname Preferred Term name of Medical Dictionary for Regulatory Activities [12], ROR reporting odds ratio, SmPC summary of product characteristics